[go: up one dir, main page]

DE60123400D1 - Gene der il-12p40 untereinheit, welche zur verbesserung der aktivität mutiert sind, und deren verwendung als adjuvans zur dna vakzinierung - Google Patents

Gene der il-12p40 untereinheit, welche zur verbesserung der aktivität mutiert sind, und deren verwendung als adjuvans zur dna vakzinierung

Info

Publication number
DE60123400D1
DE60123400D1 DE60123400T DE60123400T DE60123400D1 DE 60123400 D1 DE60123400 D1 DE 60123400D1 DE 60123400 T DE60123400 T DE 60123400T DE 60123400 T DE60123400 T DE 60123400T DE 60123400 D1 DE60123400 D1 DE 60123400D1
Authority
DE
Germany
Prior art keywords
mutant gene
dna vaccination
adjuvans
muted
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60123400T
Other languages
English (en)
Other versions
DE60123400T2 (de
Inventor
Young Chul Sung
Sung Hee Lee
Sang Jun Ha
Man Ki Song
Jun Pohang Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genexine Co Ltd
Original Assignee
Genexine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR10-2001-0012987A external-priority patent/KR100399728B1/ko
Application filed by Genexine Co Ltd filed Critical Genexine Co Ltd
Publication of DE60123400D1 publication Critical patent/DE60123400D1/de
Application granted granted Critical
Publication of DE60123400T2 publication Critical patent/DE60123400T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE60123400T 2000-03-15 2001-03-15 Gene der il-12p40 untereinheit, welche zur verbesserung der aktivität mutiert sind, und deren verwendung als adjuvans zur dna vakzinierung Expired - Lifetime DE60123400T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR2000013133 2000-03-15
KR20000013133 2000-03-15
KR2001012987 2001-03-13
KR10-2001-0012987A KR100399728B1 (ko) 2000-03-15 2001-03-13 ＩＬ-12 활성을 증가시키는 ＩＬ-12ｐ40 소단위체돌연변이 유전자 및 이를 ＤＮＡ 백신 면역증강제로이용하는 용도
PCT/KR2001/000408 WO2001068802A2 (en) 2000-03-15 2001-03-15 Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant

Publications (2)

Publication Number Publication Date
DE60123400D1 true DE60123400D1 (de) 2006-11-09
DE60123400T2 DE60123400T2 (de) 2007-08-23

Family

ID=36763001

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60123400T Expired - Lifetime DE60123400T2 (de) 2000-03-15 2001-03-15 Gene der il-12p40 untereinheit, welche zur verbesserung der aktivität mutiert sind, und deren verwendung als adjuvans zur dna vakzinierung

Country Status (10)

Country Link
US (2) US7253151B2 (de)
EP (1) EP1268759B1 (de)
JP (1) JP4180826B2 (de)
CN (1) CN1281748C (de)
AT (1) ATE340853T1 (de)
AU (2) AU3958101A (de)
CA (1) CA2402213C (de)
DE (1) DE60123400T2 (de)
ES (1) ES2272448T3 (de)
WO (1) WO2001068802A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2294213C1 (ru) * 2005-06-27 2007-02-27 Российская академия медицинских наук Государственное учреждение научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова (ГУ НИИВС им. И.И. Мечникова РАМН) Способ вакцинации против гепатита "в" детей со сниженной иммунореактивностью
KR100788930B1 (ko) * 2006-04-18 2007-12-27 포항공과대학교 산학협력단 항암 조성물
AU2007266306A1 (en) * 2006-05-26 2007-12-06 Apollo Life Sciences Limited An isolated IL-12 molecule or chimeric molecules thereof
CN101935687B (zh) * 2009-06-29 2012-11-07 中国科学院上海生命科学研究院 用IL-12p40 siRNA促进肝再生
WO2014064534A2 (en) 2012-10-05 2014-05-01 Chrontech Pharma Ab Injection needle, device, immunogenic compositions and method of use
AU2015321603A1 (en) * 2014-09-22 2017-04-13 Intrexon Corporation Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
CN109642240A (zh) * 2015-12-18 2019-04-16 昂科赛克医疗公司 异源蛋白质表达的质粒构造和使用方法
KR20220159479A (ko) 2016-05-18 2022-12-02 모더나티엑스, 인크. 인터류킨-12 (il12)를 코딩하는 폴리뉴클레오티드 및 그의 용도
JP7295795B2 (ja) 2016-07-29 2023-06-21 ジュノー セラピューティクス インコーポレイテッド 免疫調節ポリペプチドならびに関連する組成物および方法
EP3625246A1 (de) 2017-05-18 2020-03-25 ModernaTX, Inc. Polynukleotide zur codierung von gebundenen interleukin-12 (il12)-polypeptiden und verwendungen davon
PE20200862A1 (es) 2017-12-12 2020-08-25 Pionyr Immunotherapeutics Inc Anticuerpos anti-trem2 y metodos relacionados
EP3747459A4 (de) * 2018-02-02 2021-12-01 SL Vaxigen, Inc. Neuartiges impfstoffimmunadjuvans
EP3861016A2 (de) 2018-10-03 2021-08-11 Xencor, Inc. Il-12-heterodimere fc-fusionsproteine
CN109517052A (zh) * 2018-12-04 2019-03-26 江苏禄亿生生物科技有限公司 一种il-12蛋白突变体及其制备方法和应用、nk细胞培养体系和培养nk细胞的方法
CN115916233A (zh) 2019-10-03 2023-04-04 Xencor股份有限公司 靶向IL-12异源二聚体Fc融合蛋白
AU2022411048A1 (en) * 2021-12-17 2024-08-01 William Marsh Rice University Encapsulated cells expressing il-12 and uses thereof
WO2026020161A1 (en) 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013268A (en) * 1994-04-22 2000-01-11 Corixa Corporation Methods for enhancement of protective immune responses
EP0818534A1 (de) * 1996-07-12 1998-01-14 Janssen Pharmaceutica N.V. Menschliche Interleukine-12 Genexpressions-regulierende Sequenzen
US6517839B1 (en) * 1997-07-18 2003-02-11 The Regents Of The University Of California Methods for inducing interleukin-12 and a type1/Th1 T-cell response

Also Published As

Publication number Publication date
CA2402213A1 (en) 2001-09-20
EP1268759B1 (de) 2006-09-27
CN1426464A (zh) 2003-06-25
JP2003526360A (ja) 2003-09-09
US20040023332A1 (en) 2004-02-05
AU3958101A (en) 2001-09-24
CN1281748C (zh) 2006-10-25
EP1268759A2 (de) 2003-01-02
WO2001068802A3 (en) 2002-02-21
US20070269408A1 (en) 2007-11-22
ES2272448T3 (es) 2007-05-01
US7910564B2 (en) 2011-03-22
EP1268759A4 (de) 2005-09-28
ATE340853T1 (de) 2006-10-15
CA2402213C (en) 2012-08-07
AU2001239581B2 (en) 2006-01-05
JP4180826B2 (ja) 2008-11-12
WO2001068802A2 (en) 2001-09-20
US7253151B2 (en) 2007-08-07
DE60123400T2 (de) 2007-08-23

Similar Documents

Publication Publication Date Title
DE60123400D1 (de) Gene der il-12p40 untereinheit, welche zur verbesserung der aktivität mutiert sind, und deren verwendung als adjuvans zur dna vakzinierung
IL189766A0 (en) Methods for vaccine production and interferon deficient substrates
EA200401506A1 (ru) Рекомбинантный поксвирус, экспрессирующий гомологичные гены, встроенные в поксвирусный геном
DE60041280D1 (de) Chimäre mensch-rinder respiratory syncytial virus vakzinen
ATE320435T1 (de) Oxazolo-, thiazolo- und selenazolo-(4,5- c)naphthyridin-4-amine und analoge davon
CY1113241T1 (el) Μεθοδος για την παραγωγη ενεργου συστατικου ενος φαρμακευτικου ή διαγνωστικου μεσου εντος καλλιεργειας αιωρηματος κυτταρων mdck
MX2007007889A (es) Rescate del virus de influenza.
DE69736984D1 (de) Inhibitoren des interleukin-1-beta konvertierenden enzyms
ATE333284T1 (de) Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon
DE60303810D1 (de) Kontrollierte bakterielle lyse zur verabreichung von dna vakzinvektoren und impfantigen
DK1446162T3 (da) Kombinationsmotiv-immunstimulatoriske oligonukleotider med forbedret aktivitet
MX9708854A (es) Terapia de genes para regulacion de celulas efectoras.
DE69732712D1 (de) INHIBITOREN DES INTERLEUKIN-1beta KONVERTIERENDEN ENZYMS
ATE285239T1 (de) Dna enthaltende impfstoffen
ATE414761T1 (de) Verringerung der virulenz von mycobacterium tuberculosis und tuberkuloseschutz mittels inaktivierung des phop-gens
DE69833876D1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
MXPA02005506A (es) Clonacion de un gen que codifica una racemasa de aminoacido derivada de tripanosoma cruzi, y usos del mismo.
WO2003083065A3 (en) Improved methods for achieving expression from alphavirus vectors
ATE454164T1 (de) Francisella-stamm für lebenden impfstoff
ATE349530T1 (de) Nukleinsäuren und proteine des mph3 gens aus mycoplasma hypopneumoniae und deren verwendung
ATE540104T1 (de) Suspensionskultur von mykobakterien
BRPI0604365A (pt) polipeptìdeo isolado, composição de vacina anti-carrapato de múltiplas espécies, e, uso dos mesmos
ATE323772T1 (de) Regulatorische sequenzen des humanen mcp-1 gens
UA41237A (uk) Спосіб виготовлення вакцинальних алергенів
Martínez-Sobrido et al. The Specialized Proresolving Mediator

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: GENEXINE CO., LTD., SEOUL, KR